Cargando…

Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases

OBJECTIVE: To report initial results of a planned multicenter year‐long prospective study examining the risk and impact of COVID‐19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). METHODS: In April 2020, we deployed online questionnaires to individuals in...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Seth N., Venkatesh, Shruthi, Nelson, Katie E., Li, Yi, Aguerre, Ines, Zhu, Wen, Masown, Karman, Rimmer, Kathryn T., Diaconu, Claudiu I., Onomichi, Kaho B., Leavitt, Victoria M., Levine, Libby L., Strauss‐Farber, Rebecca, Vargas, Wendy S., Banwell, Brenda, Bar‐Or, Amit, Berger, Joseph R., Goodman, Andrew D., Longbrake, Erin E., Oh, Jiwon, Weinstock‐Guttman, Bianca, Thakur, Kiran T., Edwards, Keith R., Riley, Claire S., Xia, Zongqi, De Jager, Philip L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013889/
https://www.ncbi.nlm.nih.gov/pubmed/33616290
http://dx.doi.org/10.1002/acn3.51314
_version_ 1783673528253415424
author Levin, Seth N.
Venkatesh, Shruthi
Nelson, Katie E.
Li, Yi
Aguerre, Ines
Zhu, Wen
Masown, Karman
Rimmer, Kathryn T.
Diaconu, Claudiu I.
Onomichi, Kaho B.
Leavitt, Victoria M.
Levine, Libby L.
Strauss‐Farber, Rebecca
Vargas, Wendy S.
Banwell, Brenda
Bar‐Or, Amit
Berger, Joseph R.
Goodman, Andrew D.
Longbrake, Erin E.
Oh, Jiwon
Weinstock‐Guttman, Bianca
Thakur, Kiran T.
Edwards, Keith R.
Riley, Claire S.
Xia, Zongqi
De Jager, Philip L.
author_facet Levin, Seth N.
Venkatesh, Shruthi
Nelson, Katie E.
Li, Yi
Aguerre, Ines
Zhu, Wen
Masown, Karman
Rimmer, Kathryn T.
Diaconu, Claudiu I.
Onomichi, Kaho B.
Leavitt, Victoria M.
Levine, Libby L.
Strauss‐Farber, Rebecca
Vargas, Wendy S.
Banwell, Brenda
Bar‐Or, Amit
Berger, Joseph R.
Goodman, Andrew D.
Longbrake, Erin E.
Oh, Jiwon
Weinstock‐Guttman, Bianca
Thakur, Kiran T.
Edwards, Keith R.
Riley, Claire S.
Xia, Zongqi
De Jager, Philip L.
author_sort Levin, Seth N.
collection PubMed
description OBJECTIVE: To report initial results of a planned multicenter year‐long prospective study examining the risk and impact of COVID‐19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). METHODS: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID‐19 in persons with NID (PwNID) and change in their neurological care. RESULTS: Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID‐19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID‐19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID‐19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID‐19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID‐19 (OR(adj) = 1.45, 1.17–1.84). INTERPRETATIONS: Our study of real‐time, patient‐reported experience during the COVID‐19 pandemic complements physician‐reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID‐19 similar to the reference population.
format Online
Article
Text
id pubmed-8013889
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80138892021-04-01 Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases Levin, Seth N. Venkatesh, Shruthi Nelson, Katie E. Li, Yi Aguerre, Ines Zhu, Wen Masown, Karman Rimmer, Kathryn T. Diaconu, Claudiu I. Onomichi, Kaho B. Leavitt, Victoria M. Levine, Libby L. Strauss‐Farber, Rebecca Vargas, Wendy S. Banwell, Brenda Bar‐Or, Amit Berger, Joseph R. Goodman, Andrew D. Longbrake, Erin E. Oh, Jiwon Weinstock‐Guttman, Bianca Thakur, Kiran T. Edwards, Keith R. Riley, Claire S. Xia, Zongqi De Jager, Philip L. Ann Clin Transl Neurol Research Articles OBJECTIVE: To report initial results of a planned multicenter year‐long prospective study examining the risk and impact of COVID‐19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). METHODS: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID‐19 in persons with NID (PwNID) and change in their neurological care. RESULTS: Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID‐19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID‐19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID‐19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID‐19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID‐19 (OR(adj) = 1.45, 1.17–1.84). INTERPRETATIONS: Our study of real‐time, patient‐reported experience during the COVID‐19 pandemic complements physician‐reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID‐19 similar to the reference population. John Wiley and Sons Inc. 2021-02-22 /pmc/articles/PMC8013889/ /pubmed/33616290 http://dx.doi.org/10.1002/acn3.51314 Text en © 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Levin, Seth N.
Venkatesh, Shruthi
Nelson, Katie E.
Li, Yi
Aguerre, Ines
Zhu, Wen
Masown, Karman
Rimmer, Kathryn T.
Diaconu, Claudiu I.
Onomichi, Kaho B.
Leavitt, Victoria M.
Levine, Libby L.
Strauss‐Farber, Rebecca
Vargas, Wendy S.
Banwell, Brenda
Bar‐Or, Amit
Berger, Joseph R.
Goodman, Andrew D.
Longbrake, Erin E.
Oh, Jiwon
Weinstock‐Guttman, Bianca
Thakur, Kiran T.
Edwards, Keith R.
Riley, Claire S.
Xia, Zongqi
De Jager, Philip L.
Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
title Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
title_full Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
title_fullStr Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
title_full_unstemmed Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
title_short Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
title_sort manifestations and impact of the covid‐19 pandemic in neuroinflammatory diseases
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013889/
https://www.ncbi.nlm.nih.gov/pubmed/33616290
http://dx.doi.org/10.1002/acn3.51314
work_keys_str_mv AT levinsethn manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT venkateshshruthi manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT nelsonkatiee manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT liyi manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT aguerreines manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT zhuwen manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT masownkarman manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT rimmerkathrynt manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT diaconuclaudiui manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT onomichikahob manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT leavittvictoriam manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT levinelibbyl manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT straussfarberrebecca manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT vargaswendys manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT banwellbrenda manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT baroramit manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT bergerjosephr manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT goodmanandrewd manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT longbrakeerine manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT ohjiwon manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT weinstockguttmanbianca manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT thakurkirant manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT edwardskeithr manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT rileyclaires manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT xiazongqi manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT dejagerphilipl manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases
AT manifestationsandimpactofthecovid19pandemicinneuroinflammatorydiseases